Pricing pressures in US, Europe to hit Indian Pharma’s profit margins

​​The ratings agency said while revenues for these companies in FY23 will be supported by 5-7% YoY growth in the domestic market and 4-5% in the US business, revenues from the European market are expected to contract marginally.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1mxdDME
via IFTTT